<i>In Vitro</i> Activity of Cefepime-Taniborbactam against Carbapenemase-Producing <i>Enterobacterales</i> and Pseudomonas aeruginosa Isolates Recovered in Spain-Reference-Cited by-同舟云学术

In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain

Published:2022-03-15 Issue:3 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Hernández-García Marta¹²^ORCID,García-Castillo María¹²,Ruiz-Garbajosa Patricia¹²^ORCID,Bou Germán²³,Siller-Ruiz María⁴,Pitart Cristina⁵,Gracia-Ahufinger Irene⁶,Mulet Xavier²⁷,Pascual Álvaro²⁸⁹¹⁰,Tormo Nuria¹¹,Cantón Rafael¹²^ORCID

Affiliation:

1. Servicio de Microbiología, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

2. CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain

3. Servicio de Microbiología, Hospital Universitario A Coruña and Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain

4. Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla and Instituto de Investigación Sanitaria Valdecilla (IDIVAL), Santander, Spain

5. Laboratorio de Microbiología, Hospital Clínic i Provincial, Barcelona, Spain

6. UGC de Microbiología, Hospital Universitario Reina Sofía-Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain

7. Servicio de Microbiología, Hospital Universitario Son Espases and Instituto de Investigación Sanitaria Illes Balears (idISBa), Palma de Mallorca, Spain

8. Unidad de Enfermedades Infecciosas y Microbiología Clínica, Hospital Universitario Virgen Macarena, Seville, Spain

9. Departamento de Microbiología, Universidad de Seville, Seville, Spain

10. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, Seville, Spain

11. Servicio de Microbiología, Consorcio Hospital General Universitario de Valencia, Valencia, Spain

Abstract

Novel β-lactam–β-lactamase inhibitor combinations currently approved for clinical use are poorly active against metallo-β-lactamase (MBL)-producing strains. We evaluated the in vitro activity of cefepime-taniborbactam (FTB [formerly cefepime–VNRX-5133]) and comparator agents against carbapenemase-producing Enterobacterales ( n = 247) and carbapenem-resistant Pseudomonas species ( n = 170) clinical isolates prospectively collected from different clinical origins in patients admitted to 8 Spanish hospitals. FTB was the most active agent in both Enterobacterales (97.6% MIC FTB , ≤8/4 mg/L) and Pseudomonas (67.1% MIC FTB , ≤8/4 mg/L) populations.

Funder

Venatorx Pharmaceuticals

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02161-21

Reference27 articles.

1. β-Lactams and β-Lactamase Inhibitors: An Overview

2. Updated Functional Classification of β-Lactamases

3. Emerging carbapenemases: a global perspective